ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.
HOPA 2017
Durable Responses With Single-agent Ibrutinib in CLL/SLL
A study suggests that single-agent ibrutinib results in durable responses among patients with CLL or SLL.
Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis
Data suggest that most patients with MM taking immunomodulatory therapy are not receiving appropriate thromboprophylaxis.
Leflunomide May Effectively Treat CMV After Allogeneic-HSCT
The findings of this study suggest that leflunomide may be an effective treatment of CMV infection among patients who have received allo-HSCT.
Patient Burden Related to Off-Label Prescribing in Sarcoma
Data suggest that off-label prescribing may increase the time to treatment receipt, but may lower costs for patients.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in HOPA 2017
Loading... 
Loading...